Sanofi-aventis

Saint-gobain Vitrage

Synthelabo

Sanofi-synthelabo

Office National D'etudes Et De Recherches Aerospatiales

Elf Sanofi

Gilles Courtemanche

Roberto Cecchi

Tiziano Croci

Philippe Bovy

Nunzia Viviani

Ambrogio Oliva

Philippe R Bovy

Claudine Serradeil-Le Gal

Didier Jousse

Olivier Crespin

Rene Gy

Pierre Despeyroux

Stephanie Koch

Pierrick Rochard

Evelyne Fontaine

Danielle Gully

Camille G Wermuth

Pierre M Roger

Gerard Valette

Christophe Philippo

Alain Jean Braun

Cecile Pascal

Michel Parlier

Michel Jacques Geslin

Eykmar Fett

G&eacute;rard Defosse

Michel Coquillon

Marie Claire Orts

Philippe Colomban

Jean Michel Augereau

Claudie Gautier

Martine Menet

Emmanuelle Mouchon

Anne Marie Galzin

Stephen Eric O'Connor

Bruno Cornet

Claudine Serradeil Le Gal

Cécile Pascal

Alain Braun

The present invention is directed to a compound of formula (I): wherein Ar, Ar, Ar, R1 and T are as defined herein, its preparation, pharmaceutical composition and uses as orexin 2 receptor antagonist.

Sulfonamide derivatives, preparation thereof and use thereof as antagonists of orexin 2 receptors

The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an &#x2014;S(O)(C-C)alkyl group, an &#x2014;NHSO(C-C)alkyl group, an &#x2014;SONH(C-C)alkyl group, an &#x2014;NHSOphenyl-(C-C)alkyl group or an &#x2014;NHSOphenyl group, said phenyl possibly being substituted with a halogen atom, with a (C-C)alkyl group or with a (C-C)alkoxy group; Rrepresents a hydrogen atom or a (C-C)alkyl group, a &#x2014;CO(C-C)alkyl group, a phenyl-(C-C)alkyl group or a &#x2014;COphenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C-C)alkoxy group; Ris a hydrogen atom or an &#x2014;SO(C-C)alkyl group, an &#x2014;SOphenyl-(C-C)alkyl group or an &#x2014;SOphenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C-C)alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; Rrepresents a hydrogen or halogen atom, a (C-C)alkyl group, a (C-C)alkoxy group, a &#x2014;COO(C-C)alkyl group, a &#x2014;CO(C-C)alkyl group, an &#x2014;NHSO(C-C)alkyl group, an &#x2014;NHSOphenyl-(C-C)alkyl groups, &#x2014;NO, &#x2014;CN, &#x2014;CONRR, &#x2014;COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; Rand Rrepresent, independently, a hydrogen atom, a phenyl, a (C-C)alkyl group or a phenyl-(C-C)alkyl group or Rand Rwith the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.

Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same

The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

Aminotropane derivatives, preparation thereof and therapeutic use thereof

A 1-amino-phthalazine derivative of general formula (I) wherein the substituents are as defined herein. Also disclosed are a method for preparing such compounds, intermediates for use in such method and medical treatments using the compounds of formula (I).

1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof

Disclosed are compounds having the general formula (I) as defined herein, the preparation thereof, and the use thereof for the prophylaxis or treatment of any disease involving a dysfunction associated with the orexin 2 receptor such as obesity, appetite or taste disorders including cachexia, anorexia and bulimia, diabetes, metabolic syndromes, vomiting and nausea, depression and anxiety, addictions, mood and behaviour disorders, schizophrenia, sleep disorders, restless legs syndrome, memory learning disorders, sexual and psychosexual dysfunctions, pain, visceral or neuropathic pain, hyperalgesia, allodynia, digestive disorders, irritable bowel syndrome, neuronal degenerescence, ischaemic or haemorrhagic attacks, Cushing's disease, Guillain-Barr&#xe9; syndrome, myotonic dystrophy, urinary incontinence, hyperthyroidism, pituitary function disorders, hypertension or hypotension.

Sulphonamide derivatives, their preparation and their therapeutic application

The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an &#x2014;S(O)(C&#x2013;C)alkyl group, an &#x2014;NHSO(C&#x2013;C)alkyl group, an &#x2014;SONH(C&#x2013;C)alkyl group, an &#x2014;NHSOphenyl-(C&#x2013;C)alkyl group or an &#x2014;NHSOphenyl group, said phenyl possibly being substituted with a halogen atom, with a (C&#x2013;C)alkyl group or with a (C&#x2013;C)alkoxy group; Rrepresents a hydrogen atom or a (C&#x2013;C)alkyl group, a &#x2014;CO(C&#x2013;C)alkyl group, a phenyl-(C&#x2013;C)alkyl group or a &#x2014;COphenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C&#x2013;C)alkoxy group; Ris a hydrogen atom or an &#x2014;SO(C&#x2013;C)alkyl group, an &#x2014;SOphenyl-(C&#x2013;C)alkyl group or an &#x2014;SOphenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C&#x2013;C)alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; Rrepresents a hydrogen or halogen atom, a (C&#x2013;C)alkyl group, a (C&#x2013;C)alkoxy group, a &#x2014;COO(C&#x2013;C)alkyl group, a &#x2014;CO(C&#x2013;C)alkyl group, an &#x2014;NHSO(C&#x2013;C)alkyl group, an &#x2014;NHSOphenyl-(C&#x2013;C)alkyl groups, &#x2014;NO, &#x2014;CN, &#x2014;CONRR, &#x2014;COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; Rand Rrepresent, independently, a hydrogen atom, a phenyl, a (C&#x2013;C)alkyl group or a phenyl-(C&#x2013;C)alkyl group or Rand Rwith the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.

Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same

Imidazole derivatives, preparation and therapeutic application thereof

Method for producing glass sheets using flotation

2-aminoethyl-benzofuran derivatives, preparation thereof and

This invention concerns a thermally stable glass composition, which comprises the following constituents in the following proportions by weight:

Compositions of silico-sodo-calcic glasses and their applications

The invention relates to the derivatives of formula I: ##STR1## in which R.sub.1 represents a phenyl or naphthyl radical (optionally substituted), R.sub.2 represents a hydrogen or halogen atom or an alkyl, hydroxymethyl or formyl radical, R.sub.3 represents an alkyl, cycloalkyl, alkenyl, cycloalkylalkyl or phenyl radical, R.sub.4 represents a hydrogen atom or an alkyl, cycloalkyl or cycloalkylalkyl radical, R.sub.5 represents an alkyl, cycloalkyl, cycloalkylalkyl or alkenyl radical or a radical of formula B: ##STR2## (p=0, 1, 2 or 3), R.sub.6 represents a phenyl, pyridyl, imidazolyl, pyrrolyl, thienyl or furyl radical, optionally substituted, or a cycloalkyl radical,

Branched alkylamino derivatives of thiazole, processes for preparing

Woven or nonwoven long fiber sheets filled with two precursors each constituting an intermediate stage in a process for the preparation of a vitreous ceramic composition by the sol-gel route by hydrolysis and polycondensation using alcoholates or analogous compounds as the starting materials, that is to say an interface precursor in the form of a gel rich in water and a matrix precursor in the form of discrete particles capable of sintering at relatively low temperature, are stacked; the fibrous structure is compressed in the direction of stacking and the whole is heat-treated in order to convert the two precursors into a continuous matrix.

Multilayer fiber-matrix ceramic composite material and process for its

Growing community of inventors

Paris, France

Gilles Courtemanche